Oral Micronized Progesterone Cost in Vermont (2026)

What Generic Oral Micronized Progesterone Costs at Vermont Pharmacies

The average cash-pay price for a 30-day supply of generic oral micronized progesterone at Vermont retail pharmacies sits near $45 in 2026. That covers the standard 100 mg or 200 mg capsule taken nightly or on a cyclic schedule for endometrial protection during hormone replacement therapy (HRT).

Brand-name Prometrium, manufactured by AbbVie (originally developed by Solvay Pharmaceuticals), carries a manufacturer list price of approximately $180 per month. Few patients pay that figure out of pocket because multiple FDA-approved generic versions have been available since 2012. The generic products contain the same USP-grade micronized progesterone suspended in peanut oil inside a soft gelatin capsule, matching the pharmacokinetic profile established in the original Prometrium FDA approval label. Pharmacy pricing in Vermont varies by location and purchasing network: independent pharmacies in Burlington or Montpelier may price a few dollars above or below the $45 average, while chains like CVS, Walgreens, and Kinney Drugs often match or undercut it through internal discount programs.

Patients without insurance can reduce costs further by using manufacturer or third-party discount cards (covered below) or by filling at a compounding pharmacy.

How Compounded Progesterone Pricing Compares

Compounded progesterone from a licensed 503A pharmacy in Vermont costs roughly $25 per month, making it the least expensive option for patients paying cash.

Vermont permits 503A compounding pharmacies to prepare patient-specific prescriptions for oral micronized progesterone. These pharmacies operate under state Board of Pharmacy oversight and must comply with USP <795> standards for non-sterile compounding. The $25 figure reflects a custom-filled prescription using bulk pharmaceutical-grade progesterone powder, compounded into capsules at a dose specified by the prescriber.

A key distinction: compounded progesterone is not FDA-approved, and the capsules are not subject to the same bioequivalence testing required of generic Prometrium. The PEPI Trial (JAMA, 1995) used pharmaceutical-grade oral micronized progesterone (the formulation that became Prometrium) and demonstrated effective endometrial protection when paired with conjugated estrogens, with a lower rate of adverse lipid effects compared to medroxyprogesterone acetate. Whether a given compounded preparation replicates those pharmacokinetic results depends on the compounding pharmacy's quality controls.

Dr. JoAnn V. Pinkerton, past president of The North American Menopause Society, has stated: "FDA-approved micronized progesterone remains the preferred option when an approved product is available, because compounded hormones lack standardized testing for potency, purity, and bioavailability."

Patients choosing the compounded route should confirm that their Vermont pharmacy holds a current 503A license and follows USP compounding standards. Your prescriber can verify this through the Vermont Board of Pharmacy.

Vermont Medicaid Coverage for Oral Micronized Progesterone

Vermont Medicaid covers oral micronized progesterone with prior authorization (PA). The PA requirement confirms the prescriber is using progesterone for an FDA-approved indication, most commonly endometrial protection in postmenopausal women receiving estrogen therapy.

To obtain PA approval, the prescribing clinician submits documentation showing the patient has an intact uterus and is receiving or initiating estrogen-based HRT. Vermont's Department of Vermont Health Access (DVHA) processes most PA requests within 24 to 72 hours. Generic oral micronized progesterone is placed on the Vermont Medicaid preferred drug list, so once PA is granted, patient cost-sharing is minimal: typically a $1 to $3 copay per fill.

Brand Prometrium may require a non-preferred PA, adding an extra step. Prescribers must demonstrate medical necessity (for instance, a documented peanut-oil allergy requiring an alternative formulation would not apply here since both brand and generic use peanut oil, but a documented adverse reaction to a specific generic manufacturer's inactive ingredients could qualify).

For Medicaid-enrolled patients, the generic version at a $1 to $3 copay represents the most cost-effective path. Compounded progesterone is generally not covered by Vermont Medicaid, since the program restricts reimbursement to FDA-approved products with National Drug Codes (NDCs).

Which Commercial Insurance Plans Cover Progesterone in Vermont

Most commercial insurance plans sold in Vermont, including those on Vermont Health Connect (the state's ACA marketplace), cover generic oral micronized progesterone at Tier 1 or Tier 2 formulary placement. That translates to a $5 to $25 copay per month for the majority of enrollees.

Blue Cross Blue Shield of Vermont (BCBSVT), MVP Health Care, and Cigna, the three largest carriers in the state, all list generic progesterone as a preferred generic on their 2026 formularies. A Tier 1 placement means generic oral micronized progesterone is treated like a standard generic medication with the lowest copay tier available under the plan.

Brand-name Prometrium typically falls on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), depending on the carrier and specific plan. Copays at those tiers range from $40 to $75. Because the active ingredient is identical, most plans enforce step therapy requiring a trial of generic progesterone before approving brand Prometrium.

Patients with high-deductible health plans (HDHPs) pay the full negotiated rate until meeting their deductible. The negotiated rate for generic progesterone through a PBM like Express Scripts or CVS Caremark is often $15 to $35, which is actually lower than the $45 average cash price.

The Endocrine Society's 2022 clinical practice guideline on menopausal hormone therapy recommends micronized progesterone as first-line progestogen for endometrial protection in women with a uterus receiving systemic estrogen, noting its favorable cardiovascular and breast safety profile compared to synthetic progestins (Endocrine Society, JCEM 2022).

Discount Programs and Savings Cards Available in Vermont

Several discount pathways can lower out-of-pocket costs for Vermont residents who are uninsured, underinsured, or facing high copays.

Manufacturer savings cards. AbbVie offers a Prometrium savings card that may reduce brand copays to as low as $25 per fill for commercially insured patients. The card does not apply to government-funded insurance (Medicaid, Medicare Part D, TRICARE). Eligibility and terms change annually, so patients should check the program's current status at the point of prescribing.

GoodRx, RxSaver, and similar aggregators. These platforms negotiate pharmacy-level discount pricing and routinely show Vermont prices for generic oral micronized progesterone between $20 and $40 for a 30-day supply. Prices vary by pharmacy: a GoodRx coupon at one Burlington pharmacy might yield $22, while the same coupon at a different chain five miles away shows $38. Patients should compare prices across at least three pharmacies before filling.

340B pricing. Federally qualified health centers (FQHCs) and certain hospitals in Vermont participate in the 340B Drug Pricing Program, which allows these entities to purchase medications at steep discounts. Patients who receive care at a 340B-covered facility, such as Community Health Centers of Burlington, may access generic progesterone at significantly reduced cost. Savings depend on the facility's 340B contract pharmacy arrangements.

Vermont pharmacy assistance. Vermont does not operate a standalone state pharmaceutical assistance program for non-Medicare adults as of 2026, but the state's premium assistance programs through Vermont Health Connect can indirectly reduce drug costs by lowering overall plan cost-sharing.

For most uninsured Vermont residents, the combination of a GoodRx-type coupon at a retail pharmacy ($20 to $40) or a compounded preparation ($25) represents the floor price without insurance.

Telehealth Prescribing of Oral Micronized Progesterone in Vermont

Vermont law permits telehealth prescribing of oral micronized progesterone. A clinician licensed in Vermont can evaluate a patient via synchronous video or audio visit, establish the clinical indication, and transmit the prescription electronically to any Vermont pharmacy.

Vermont expanded its telehealth parity laws during and after the COVID-19 public health emergency. Act 140 (2020) and subsequent legislation require commercial insurers to reimburse telehealth visits at the same rate as in-person visits for the same service. This means a telehealth consultation for HRT management, including the prescribing of oral micronized progesterone, is covered the same as an office visit under most Vermont plans.

Patients in rural areas of Vermont, including the Northeast Kingdom and parts of Bennington and Windham counties, benefit from telehealth access since the nearest endocrinologist or menopause specialist may be 60 or more miles away. HealthRX offers telehealth HRT consultations with board-certified clinicians who can prescribe oral micronized progesterone and coordinate fills at the patient's preferred Vermont pharmacy.

A clinical note on dosing: the standard regimen is 200 mg nightly for 12 days per calendar month (cyclic use) or 100 mg nightly continuously, both taken at bedtime because progesterone causes drowsiness. The PEPI Trial (N=875) demonstrated that 200 mg cyclic micronized progesterone provided endometrial protection equivalent to 10 mg cyclic medroxyprogesterone acetate, with significantly better HDL cholesterol preservation (a 4.1% increase vs. no significant change in the MPA group) (Writing Group for the PEPI Trial, JAMA 1995).

How Vermont Compares to Neighboring States

Vermont's $45 average cash price for generic oral micronized progesterone is competitive with, but not meaningfully different from, neighboring New England states. New Hampshire averages $42 to $48, Massachusetts $40 to $50, and New York $38 to $52, depending on pharmacy and location.

Where Vermont stands out is in its Medicaid coverage posture. Vermont's Medicaid program covers oral micronized progesterone with PA, while some states impose additional quantity limits or require failure of a synthetic progestin first. Vermont does not require step therapy through medroxyprogesterone acetate before approving micronized progesterone under Medicaid, which aligns with The North American Menopause Society (NAMS) 2022 position statement recommending micronized progesterone as the preferred progestogen option due to its "more favorable effect on lipids and potentially on breast cancer risk compared to synthetic progestins."

Vermont's 503A compounding access also remains intact. Some states have tightened compounding regulations following FDA enforcement actions against non-compliant pharmacies, but Vermont's Board of Pharmacy maintains a clear licensure pathway for 503A pharmacies operating within the state.

What to Ask Your Prescriber About Cost

Before filling a prescription for oral micronized progesterone in Vermont, three questions can save meaningful money.

First, confirm generic substitution is permitted on the prescription. Vermont law allows automatic generic substitution unless the prescriber writes "brand medically necessary." If the prescription specifies Prometrium with no substitution, you could pay $180 instead of $45.

Second, ask whether a 90-day supply is an option. Many insurance plans and discount programs offer a per-unit price reduction for 90-day fills, and Vermont pharmacies can dispense 90-day supplies for maintenance medications. A 90-day generic fill might run $100 to $120 cash (versus $135 for three separate 30-day fills).

Third, if cost remains a barrier, ask about compounded progesterone and whether your clinician is comfortable prescribing it. The E3N French cohort study (N=80,377) found that women using micronized progesterone combined with transdermal estradiol had no statistically significant increase in breast cancer risk over a mean follow-up of 8.1 years (RR 1.00 to 95% CI 0.83 to 1.22), reinforcing the clinical rationale for choosing this specific progestogen (Fournier et al., Breast Cancer Res Treat, 2008).

Your prescriber should be informed about the cost differential between FDA-approved generic ($45/month), compounded ($25/month), and brand ($180/month) options to help you make a decision that balances clinical evidence, regulatory assurance, and affordability.